Primary objective:

To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.

Secondary objective:

To assess tumor control and survival

Inclusion Criteria:

• International Union against Cancer stages III and IV newly diagnosed NPC

Exclusion Criteria:

• Inadequate bone marrow reserve
• Inadequate renal function
• Other primary malignancy
• Evidence of distant metastases

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.